Scientific contribution

The DMSR has alone or in collaboration with other scientists published more than 130 scientific papers in the fields listed below. By clicking the header, you will get a list of the most important studies within the respective field.

Descriptive epidemiology
Incidence of MS has increased markedly, particularly in elderly and in women.
Incidence of NMOSD in Denmark was estimated at 0.029 per 100,000 person years.
The incidence rates of paediatric MS and other ADS in Denmark were higher than those reported for some other European countries.
Spatial analyses revealed that even within the small geographical area of Denmark there were significant variations in MS incidence.
Historical prospective studies
Low concentrations of neonatal 25(OD) vitamin D increases the risk of MS later in life.
Shift work at young age 15-19 increases the risk of MS in adulthood.
MS seems to considerably impact reproductive choices.
Immigrants from low-MS-risk countries only partially adapted to the risk in Denmark, most pronounced with immigration before age 15.
Early age at menarche appears to be associated with an increased risk of MS.
Socioeconomic status in childhood seems of no major importance for the subsequent risk of MS.
People born by Caesarean section were at no increased risk of MS later in life.
Use of antibiotics increases the risk of MS suggesting that the underlying infections may be causally associated with MS.
High body mass index in childhood is a risk factor for MS.
Male infertility increases the risk of MS.
Parental MS affects educational achievements, employment, disability pension and income of children.
Cohort observational studies
Relapses worsen disability significantly beyond the recovery phase.
Surviving times in patients with MS have improved steadily over several decades.
The efficacy of DMT in paediatric onset MS patients is comparable to that seen in adult onset MS patients.
Earlier treatment start is associated with a beneficial prognosis in the paediatric cohort.
Patients who started treatment with DMT later reached an EDSS score of 6 more quickly compared with patients who started early, and the delay showed a tendency to shorten time to death.
MS patients do not have increased cancer incidence or increased cancer-specific mortality compared with the background population.
Compared with the background population MS seriously affects the economic life of the patients, even within a few years of onset.
Compared with the background population MS often leads to broken relationships.
Treatment effectiveness of Interferon-β is not different in women and men.
Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis.
Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
The occurrence of vascular comorbidities is higher in the population with MS.
Comorbidities in MS have socioeconomic consequences and are associated with diagnostic delays and increased mortality.
Case-control studies
Female MS patients have fewer childbirths than women from the matched background population in the last five years up to clinical onset.
Social and physical environmental factors available from Danish registries cannot explain the increasing incidence of women in Denmark.
Some autoimmune comorbidities are more frequent in persons with MS.
Head-to-head treatment comparison studies.
Reduced disease activity in MS patients treated with dimethyl fumarate compared with patients treated with teriflunomide.
Natalizumab and fingolimod had equal clinical effect in RRMS.
The Danish Multiple Sclerosis Registry © 2020 All Rights Reserved